// App-Quantinova.ai

1445 : STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity

Researchers

Presenter

  • Laura Hix Glickman

Principal Investigators

  • Shailaja Kasibhatla

  • Jie Li

  • Anne Marie Culazzo

  • Kelsey Sivick Gauthier

  • Weiwen Deng

  • Anthony L. Desbien

  • George E. Katibah

  • Justin J. Leong

  • Leonard Sung

  • Ken Metchette

  • Chudi Ndubaku

  • Lianxing Zheng

  • Charles Cho

  • Yan Feng

  • Jeffrey M. McKenna

  • John A. Tallarico

  • Steven L. Bender

  • Thomas W. Dubensky

  • Sarah M. McWhirter

Medical Centers

  • Aduro Biotech, Inc., Berkeley, CA

  • Genomics Institute of the Novartis Research Foundation, San Diego, CA.

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

Locations

  • United States

Companies

  • Aduro Biotech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of differentiation 8A

  • Interferon

Drug/Treatment

  • Interferon

  • ADUS100

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved